SPECIALTY GUIDELINE MANAGEMENT

SABRIL (vigabatrin)

POLICY

I. INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered covered benefits provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

A. FDA-Approved Indications
   1. Infantile spasms: Sabril is indicated as monotherapy for pediatric patients with infantile spasms one month to two years of age for whom the potential benefits outweigh the potential risk of vision loss.
   2. Complex Partial Seizures: Sabril is indicated as adjunctive therapy for adults and pediatric patients ten years of age and older with refractory complex partial seizures who have inadequately responded to several alternative treatments and for whom the potential benefits outweigh the risk of vision loss. Sabril is not indicated as a first line agent for complex partial seizures.

B. Compendial Use: Refractory complex partial seizures in children younger than ten years of age who have inadequately responded to at least two alternative treatments.

All other indications are considered experimental/investigational and are not covered benefits.

II. CRITERIA FOR INITIAL APPROVAL

A. Infantile Spasms
   Authorization of 4 weeks may be granted for the treatment of infantile spasms when Sabril is used as a single agent (monotherapy).

B. Complex Partial Seizures
   Authorization of 3 months may be granted for the treatment of complex partial seizures when both of the following criteria are met:
   1. Sabril will be used as adjunctive therapy
   2. Member has had an inadequate response to at least two alternative treatments for complex partial seizures

III. CONTINUATION OF THERAPY

A. Infantile Spasms
   Authorization of 6 months may be granted for members requesting Sabril for continuation of therapy when member has shown substantial clinical benefit from Sabril therapy.

B. Complex Partial Seizures
   Authorization of 12 months may be granted for members requesting Sabril for continuation of therapy when member has shown substantial clinical benefit from Sabril therapy.
IV. DOSAGE AND ADMINISTRATION

Approvals may be subject to dosing limits in accordance with FDA-approved labeling, accepted compendia, and/or evidence-based practice guidelines. The following dosing limit applies (for complex partial seizures only): 3,000 mg per day.

V. REFERENCES